These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

292 related items for PubMed ID: 21046526

  • 1. Lixivaptan, a non-peptide vasopressin V2 receptor antagonist for the potential oral treatment of hyponatremia.
    Ghali JK, Zmily HD, Farah JO, Daifallah S.
    IDrugs; 2010 Nov; 13(11):782-92. PubMed ID: 21046526
    [Abstract] [Full Text] [Related]

  • 2. The potential role for lixivaptan in heart failure and in hyponatremia.
    Zmily HD, Khan NS, Daifallah S, Ghali JK.
    Expert Opin Investig Drugs; 2011 Jun; 20(6):831-48. PubMed ID: 21548825
    [Abstract] [Full Text] [Related]

  • 3. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1615-21. PubMed ID: 16630999
    [Abstract] [Full Text] [Related]

  • 4. Lixivaptan (American Home Products).
    Martinez-Castelao A.
    Curr Opin Investig Drugs; 2001 Apr 18; 2(4):525-30. PubMed ID: 11566011
    [Abstract] [Full Text] [Related]

  • 5. Difference in solute excretion during correction of hyponatremic patients with cirrhosis or syndrome of inappropriate secretion of antidiuretic hormone by oral vasopressin V2 receptor antagonist VPA-985.
    Decaux G.
    J Lab Clin Med; 2001 Jul 18; 138(1):18-21. PubMed ID: 11433224
    [Abstract] [Full Text] [Related]

  • 6. [Vasopressin receptor antagonists: the vaptans].
    Villabona C.
    Endocrinol Nutr; 2010 May 18; 57 Suppl 2():41-52. PubMed ID: 21130961
    [Abstract] [Full Text] [Related]

  • 7. Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
    Palm C, Pistrosch F, Herbrig K, Gross P.
    Am J Med; 2006 Jul 18; 119(7 Suppl 1):S87-92. PubMed ID: 16843091
    [Abstract] [Full Text] [Related]

  • 8. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial.
    Wong F, Blei AT, Blendis LM, Thuluvath PJ.
    Hepatology; 2003 Jan 18; 37(1):182-91. PubMed ID: 12500203
    [Abstract] [Full Text] [Related]

  • 9. Treatment of hyponatremia: the role of lixivaptan.
    Liamis G, Filippatos TD, Elisaf MS.
    Expert Rev Clin Pharmacol; 2014 Jul 18; 7(4):431-41. PubMed ID: 24766294
    [Abstract] [Full Text] [Related]

  • 10. Vasopressin-receptor antagonists.
    Hoorn EJ, Zietse R.
    Future Cardiol; 2010 Jul 18; 6(4):523-34. PubMed ID: 20608824
    [Abstract] [Full Text] [Related]

  • 11. Evaluation of lixivaptan in euvolemic and hypervolemic hyponatremia and heart failure treatment.
    Zmily HD, Alani A, Ghali JK.
    Expert Opin Drug Metab Toxicol; 2013 May 18; 9(5):645-55. PubMed ID: 23570283
    [Abstract] [Full Text] [Related]

  • 12. Recognition and treatment of hyponatremia in acutely ill hospitalized patients.
    Patel GP, Balk RA.
    Clin Ther; 2007 Feb 18; 29(2):211-29. PubMed ID: 17472815
    [Abstract] [Full Text] [Related]

  • 13. Lixivaptan: a novel vasopressin receptor antagonist.
    Ku E, Nobakht N, Campese VM.
    Expert Opin Investig Drugs; 2009 May 18; 18(5):657-62. PubMed ID: 19379124
    [Abstract] [Full Text] [Related]

  • 14. Treatment of hypervolemic or euvolemic hyponatremia associated with heart failure, cirrhosis, or the syndrome of inappropriate antidiuretic hormone with tolvaptan: a clinical review.
    Nemerovski C, Hutchinson DJ.
    Clin Ther; 2010 Jun 18; 32(6):1015-32. PubMed ID: 20637957
    [Abstract] [Full Text] [Related]

  • 15. Peptide and non-peptide agonists and antagonists for the vasopressin and oxytocin V1a, V1b, V2 and OT receptors: research tools and potential therapeutic agents.
    Manning M, Stoev S, Chini B, Durroux T, Mouillac B, Guillon G.
    Prog Brain Res; 2008 Jun 18; 170():473-512. PubMed ID: 18655903
    [Abstract] [Full Text] [Related]

  • 16. Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.
    Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.
    Cardiovasc Drug Rev; 2007 Jun 18; 25(1):1-13. PubMed ID: 17445084
    [Abstract] [Full Text] [Related]

  • 17. Vasopressin dysregulation: hyponatremia, fluid retention and congestive heart failure.
    LeJemtel TH, Serrano C.
    Int J Cardiol; 2007 Aug 09; 120(1):1-9. PubMed ID: 17346825
    [Abstract] [Full Text] [Related]

  • 18. Hyponatremia in heart failure: the role of arginine vasopressin and its antagonism.
    Rosner MH, Ronco C.
    Congest Heart Fail; 2010 Jul 09; 16 Suppl 1():S7-14. PubMed ID: 20653716
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Komai Y, Thandavarayan RA, Sukumaran V, Watanabe K.
    Drug Discov Today; 2010 Oct 09; 15(19-20):826-41. PubMed ID: 20708094
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.